Fluidigm Corporation announced the closing of the previously announced strategic capital infusion from Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). As previously announced, Dr. Michael Egholm will become Chief Executive Officer. Fluidigm CEO Chris Linthwaite has stepped down and will remain in an advisory role until November 30, 2022, to ensure a smooth transition.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.4 USD | -0.41% | -4.38% | +8.60% |
May. 08 | Transcript : Standard BioTools Inc., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Earnings Flash (LAB) STANDARD BIOTOOLS Reports Q1 Revenue $45.5M, vs. Street Est of $46M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.60% | 918M | |
+11.73% | 226B | |
+9.53% | 188B | |
+14.63% | 137B | |
+27.47% | 108B | |
-0.04% | 63.19B | |
+13.73% | 52.26B | |
+4.86% | 51B | |
+7.72% | 43.89B | |
+7.86% | 38.07B |
- Stock Market
- Equities
- LAB Stock
- News Standard BioTools Inc.
- Fluidigm Corporation Announces CEO Changes